Meningitis, Bacterial, Pneumonia, Bacterial, Pneumonia, Viral
Conditions
Keywords
surveillance study, prospective, observational, health center-based, pneumonia, bacterial, pneumonia, viral, meningitis, bacterial, Africa south of the Sahara
Brief summary
The aim of this study is to estimate the burden of disease due to pneumococci, other bacteria and viruses in the African meningitis belt prior to pneumococcal conjugate vaccine introduction and to estimate the population impact of the vaccine after its implementation in 2014. In a defined population of a sanitary district in northern Togo, during the period 2010 to 2017, investigators enroll patients of all ages with suspected pneumonia requiring hospitalization or suspected bacterial meningitis. Patients are evaluated by bacteriology and molecular biology techniques on blood, cerebro-spinal fluid, nasal aspirates and by chest X-ray.
Interventions
None listed
Sponsors
Region Sanitaire des Savanes, Togo
Ministere de la Sante et de la Promotion Sociale, Togo
Institut National d'Hygiene, Togo
Centre Muraz
Fondation Mérieux, France
Pfizer
Agence de Médecine Préventive, France
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
Pneumonia surveillance: Inclusion Criteria: * resident of Tône sanitary district - requiring hospitalisation for at least one night for clinical pneumonia syndrome * hospitalised in a study site during the study period
Exclusion criteria
* absence of informed consent by patient or legal tutor Meningitis surveillance: Inclusion Criteria: * resident of Tône sanitary district * presenting clinical signs of acute bacterial meningitis * hospitalised in a study site during the study period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of pneumococcal pneumonia requiring hospitalisation, confirmed by blood culture or PCR analysis of blood | Subjects will be enrolled on admission to hospital and followed for the duration of hospitalization (median duration 6 days) |
| Incidence of pneumococcal meningitis, confirmed by culture or PCR on cerebro-spinal fluid | Subjects will be enrolled on admission to hospital and followed for the duration of hospitalization (median duration 6 days) |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of suspected pneumonia requiring hospitalisation with reduced oxygen saturation (<90%) | Subjects will be enrolled on admission to hospital and followed for the duration of hospitalization (median duration 6 days) |
| Incidence of radiologically confirmed pneumonia requiring hospitalisation | Subjects will be enrolled on admission to hospital and followed for the duration of hospitalization (median duration 6 days) |
| Incidence of acute meningitis of other bacterial etiology | Subjects will be enrolled on admission to hospital and followed for the duration of hospitalization (median duration 6 days) |
| Incidence of pneumonia of other bacterial or viral etiology requiring hospitalisation | Subjects will be enrolled on admission to hospital and followed for the duration of hospitalization (median duration 6 days) |
| Incidence of suspected pneumonia requiring hospitalisation with elevated C-reactive protein serum concentration (<40mg/l) | Subjects will be enrolled on admission to hospital and followed for the duration of hospitalization (median duration 6 days) |
Countries
Togo
Contacts
Primary ContactMakawa-Sy Makawa, MD
Backup ContactHaoua Tall, PharmD MPH
Outcome results
None listed